跳轉至內容
Merck
全部照片(1)

Key Documents

View All Documentation

SML2378

Sigma-Aldrich

Dalbavancin

≥90% (HPLC)

同義詞:

5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methyl-1-oxoundecyl)amino]-β-Dglucopyranuronosyl]-38-[[[3-(dimethylamino)propyl]amino]carbonyl]-42-O-α-D-mannopyranosyl-N15-methyl- Ristomycin A aglycone, BI 397, BI-397, BI397, MDL 63,397, MDL 63397, MDL-63,397, MDL-63397, MDL63,397, MDL63397, Ristomycin A aglycone, VER 001, VER-001, VER001

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C88H100Cl2N10O28
CAS號碼:
171500-79-1
分子量：:
1816.69
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥90% (HPLC)

形狀

powder

顏色

white to beige

溶解度

H2O: 2 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

O=C([C@@]1([H])NC([C@](C2)([H])NC([C@@H](C3=CC(OC4=CC1=C(Cl)C(O)=C4)=C(O)C=C3)NC)=O)=O)N[C@@](C5=CC(OC6=CC=C2C=C6)=C(O[C@H]7[C@H](NC(CCCCCCCCC(C)C)=O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O7)C(OC8=C(Cl)C=C([C@@]9([H])O)C=C8)=C5)([H])C(N[C@@]%10([H])C(N[C@]9([H])

InChI

1S/C88H100Cl2N10O28/c1-38(2)13-10-8-7-9-11-14-61(106)93-69-73(109)75(111)78(86(120)121)128-87(69)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)68-84(118)97-66(80(114)91-25-12-26-99(3)4)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)64(81(115)98-68)94-82(116)65(43)95-83(117)67-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)70(100(5)6)85(119)92-51(79(113)96-67)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,101-105,107-112H,7-14,25-27,37H2,1-6H3,(H,91,114)(H,92,119)(H,93,106)(H,94,116)(H,95,117)(H,96,113)(H,97,118)(H,98,115)(H,120,121)/t51-,60-,64-,65-,66+,67+,68+,69-,70-,71-,72-,73-,74+,75+,76+,78+,87?,88+/m1/s1

InChI 密鑰

NECNEVHRBQBTTH-SOWMDMGUSA-N

生化／生理作用

Dalbavancin is a semisynthetic, vancomycin class lipoglycopeptide with antibacterial activity against a variety of gram-positive pathogens, including methicillin-resistant S. aureus & S. epidermidis (MRSA & MRSE), but not gram-negative or vancomycin-resistant enterococci that possess VanA gene. Similar to vancomycin and other class members (e.g. teicoplanin, telavancin, ramoplanin, and ritavancin), dalbavancin disrupts bateria cell wall formation and cell membrane integrity by targeting the D-alanyl-D-alanyl residues on the growing peptidoglycan chains, blocking transpeptidation and peptidoglycan elongation.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Katharina Neudorfer et al.
Diagnostic microbiology and infectious disease, 90(1), 58-63 (2017-12-03)
We tested the in vitro activity of dalbavancin, vancomycin and daptomycin against 83 enterococcal isolates in planktonic and biofilm states. The MIC90 for vancomycin-susceptible Enterococcus faecalis was 0.125 and 4μg/mL for dalbavancin and daptomycin, respectively. For vancomycin-resistant Enterococcus faecium, the
Helio S Sader et al.
Antimicrobial agents and chemotherapy, 62(3) (2017-12-22)
Dalbavancin activity was assessed against a large collection of Staphylococcus aureus isolates (n = 59,903), including isolates with decreased susceptibility to vancomycin (MIC, ≥2 mg/liter; n = 1,141), daptomycin (MIC, ≥2 mg/liter; n = 48), telavancin (MIC, ≥0.12 mg/liter; n
Zongru Guo
Acta pharmaceutica Sinica. B, 7(2), 119-136 (2017-03-18)
Drug innovation is characterized by painstaking molecular-level syntheses and modifications as the basic components of research and development. Similarly, natural products are chemically tailored and modified based upon their structural and biological properties. To some extent, the modification of natural
Michael A Pfaller et al.
International journal of antimicrobial agents, 51(4), 608-611 (2017-12-27)
Osteomyelitis is a difficult-to-treat infection that regularly involves prolonged use of systemic antibiotics. Dalbavancin has demonstrated activity against Gram-positive isolates, and has been considered as a candidate for the treatment of osteomyelitis in adults and children. This study evaluated the
Valentin Al Jalali et al.
Clinical pharmacokinetics, 57(7), 797-816 (2018-01-15)
Telavancin was discovered by modifying the chemical structure of vancomycin and belongs to the group of lipoglycopeptides. It employs its antimicrobial potential through two distinct mechanisms of action: inhibition of bacterial cell wall synthesis and induction of bacterial membrane depolarization
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務